Peptide receptor radionuclide therapy (PRRT) is an approved and efficient therapy for patients with somatostatin type-2 receptor (SSTR2) positive neuroendocrine tumors (NETs). The gene discussed is SSTR2; the disease is neuroendocrine neoplasm.